The room was packed and elec­tric. That’s how it felt host­ing an event in per­son for End­points News read­ers last month in San Diego.

It ex­ceed­ed all our ex­pec­ta­tions, which wasn’t a giv­en, with the pan­dem­ic chang­ing the na­ture of live events. We hadn’t done one in over two years. And End­points grew a lot dur­ing that time. We quick­ly built a se­ri­ous vir­tu­al events plat­form and de­vel­oped big au­di­ences around those on­line chan­nels. But there’s noth­ing quite like be­ing with your col­leagues at a live event. End­points has a tra­di­tion of con­ven­ing our au­di­ence of bio­phar­ma pros in ma­jor hubs world­wide since our start in 2016. And we’re thrilled to jump right back in.

With a wrap on BIO, AS­CO, Cannes and oth­er crit­i­cal in­dus­try mee­tups, there are sev­er­al key dates ahead on the End­points cal­en­dar to at­tend — both live and in-per­son. And spon­sor­ship op­por­tu­ni­ties re­main for bio­phar­ma mar­keters. Here’s what’s on deck:

Ma­jor End­points events

The End­points 11 (Sep­tem­ber 22, Boston) — Big dreams dom­i­nate among next-gen biotech play­ers. Our an­nu­al E11 se­ries is back to hon­or the up­starts most poised for im­pact — an event that al­so marks John Car­roll’s 20th year spot­light­ing pri­vate biotechs. Join us vir­tu­al­ly or in per­son at an ex­clu­sive event in Boston. Past events: 2021, 2020 | Cov­er­age: 2021, 2020

#EU­BIO22 (Oc­to­ber 12, Lon­don) — The bio­phar­ma view from the con­ti­nent. Read­ers can sign up to stream the full line­up — or pur­chase a tick­et to join us in Lon­don that af­ter­noon — as John Car­roll and Sil­i­con Val­ley Bank’s Nooman Haque host a se­ries of pan­els and fire­side chats as­sess­ing the lat­est M&A, R&D and reg­u­la­to­ry trends fac­ing Eu­rope’s bio­phar­ma in­dus­try.

Women in Bio­phar­ma (De­cem­ber 7, vir­tu­al) — Tak­ing the lead in R&D. You won’t want to miss one of our most pop­u­lar an­nu­al re­ports pro­fil­ing 20 of the in­dus­try’s most in­flu­en­tial women ex­ec­u­tives. Our ed­i­tors will host a spe­cial pre­sen­ta­tion high­light­ing this year’s hon­orees and sub­se­quent pan­el dis­cus­sion prob­ing what’s ahead for di­ver­si­ty and in­clu­sion ini­tia­tives.

Con­fer­ence cov­er­age and events

#ES­MO22 (Sep­tem­ber 12, vir­tu­al) — What’s new in on­col­o­gy in R&D? Our jour­nal­ists will re­port live from Paris with break­ing news and read­outs from the show and re­lease a spe­cial ES­MO re­port on Sep­tem­ber 12. You can al­so tune in live for EIC John Car­roll’s vir­tu­al fire­side with a lead­ing news­mak­er at ES­MO and his sub­se­quent pan­el analy­sis of the con­fer­ence’s biggest wins and loss­es.

#ASH22 (De­cem­ber 12, vir­tu­al) — Cell and gene ther­a­pies are head­ed to crit­i­cal mile­stones. Our glob­al au­di­ence can livestream John Car­roll’s fire­side chat and pan­el re­view un­pack­ing the in­dus­try’s most close­ly watched cell and gene ther­a­pies. If you miss the livestream, you’ll find this year’s spe­cial ASH re­port in your in­box on De­cem­ber 12.

#CPHI (Oc­to­ber 27, spe­cial re­port) — End­points Man­u­fac­tur­ing will have a spe­cial edi­tion cov­er­ing the lat­est in­no­va­tions in phar­ma man­u­fac­tur­ing and de­vel­op­ment in ad­vance of the big CPHI event in Frank­furt.

And, as al­ways, our sum­mer sights are set square­ly in San Fran­cis­co this Jan­u­ary for JP Mor­gan. More to come as we pre­pare for wall-to-wall cov­er­age at the in­dus­try’s pre­mier kick­off event.

For all event ad­ver­tis­ing, sched­ul­ing and pric­ing re­quests, con­tact our sales team di­rec­tors Melis­sa Naz­zaro (melis­sa@end­pointsnews.com) and Julie No­tario (jno­tario@end­pointsnews.com).

For our full me­dia kit, vis­it End­points Stu­dio — our in-house mar­ket­ing agency led by Kari Abit­bol that con­nects bio­phar­ma mar­keters with their tar­get au­di­ences di­rect­ly on the End­points plat­form.

If you want to reach out to the ed­i­to­r­i­al team with sug­ges­tions, email ed­i­tor@end­pointsnews.com.

Dupixent, the blockbuster anti-inflammatory drug from Sanofi and Regeneron, has cleared a high-stakes Phase III study in chronic obstructive pulmonary disease, the companies announced Thursday morning.

If they hold up in a second, identical trial, the data pave the way for Dupixent to become the first biologic to treat patients whose COPD remains uncontrolled despite being on maximal standard-of-care inhaled therapy — the patient population studied in the pivotal program. The companies had spotlighted this as a key readout as they look to expand the Dupixent franchise and explore its full potential.

Incyte touted an accelerated approval for its PD-1 retifanlimab in a rare skin cancer on Wednesday, roughly a year and a half after the drug suffered a rejection in squamous cell carcinoma of the anal canal (SCAC).

Retifanlimab, marketed as Zynyz, was approved for metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a fast-growing skin cancer typically characterized by a single, painless nodule. It’s roughly 40 times rarer than melanoma, according to the nonprofit Skin Cancer Foundation — but incidence is growing, particularly among older adults, Incyte said in its announcement.

Novartis is calling off a UK-based trial for Leqvio in the primary prevention of cardiovascular events in patients with high cholesterol, the company confirmed on Wednesday.

The Swiss pharma giant made the decision after “careful evaluation,” a spokesperson told Endpoints News via email. The trial, dubbed ORION-17, was planned in partnership with England’s National Health Service (NHS) and was part of the company’s strategy to establish Leqvio as a standard of care in cardiovascular disease management.